Human 5-, 12- and 15-lipoxygenase-1 coexist in kidney but show opposite trends and their balance changes in cancer

Oncology Reports

Volumn 28, Issue 4, 2012, Pages 1275-1282

  Gohara, Amira ^a   Eltaki, Noha ^a   Sabry, Dina ^a   Murtagh, Daniel ^a   Jankun, Jerzy ^a,b,c   Selman, Steven H ^a   Skrzypczak Jankun, Ewa ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Human lipoxygenases; Hypertension; RCC management; Renal carcinoma; Specific antibodies

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE 1; ARACHIDONATE 5 LIPOXYGENASE; BIOLOGICAL MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PAPILLARY CARCINOMA; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84866464877     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1924     Document Type: Article

References (22)

1. Chow WH, Dong L and Devesa S: Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7: 245-257, 2010.
2. American Cancer Society: Cancer Facts and Figures 2011. American Cancer Society, Atlanta, 2011.
3. Heng DY, Xie W, Bjarnason GA, et al: Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer 117: 2637-2642, 2011.
4. Berglund L, Björling E, Oksvold P, et al: A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics 7: 2019-2027, 2008.
5. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al: Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9: 166-180, 2007.
6. Pontén F, Jirström K and Uhlen M: The Human Protein Atlas - a tool for pathology. J Pathol 216: 387-393, 2008.
7. Haeggström JZ and Funk CD: Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev 111: 5866-5898, 2011.
8. Skrzypczak-Jankun E, Chorostowska-Wynimko J, Selman SH and Jankun J: Lipoxygenases - a challenging problem in enzyme inhibition and drug development. Curr Enzym Inhib 3: 119-132, 2007.
9. Kulkarni AP: Lipoxygenase - a versatile biocatalyst for biotransformation of endobiotics and xenobiotics. Cell Mol Life Sci 58: 1805-1825, 2001.
10. Fleming ID, Cooper JS, Henson DE, et al (eds.): AJCC Cancer Staging Manual. Lippincott-Raven, Philadelphia, 1997.
11. Sibony M and Vieillefond A: Non-clear cell renal cell carcinoma. 2008 update in renal tumor pathology. Ann Pathol 28: 381-401, 2008 (In French).
12. Wang D and Dubois RN: Eicosanoids and cancer. Nat Rev Cancer 10: 181-193, 2010.
13. Faronato M, Muzzonigro G, Milanese G, et al: Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma. Histol Histopathol 22: 1109-1118, 2007.
14. Matsuyama M, Yoshimura R, Mitsuhashi M, et al: 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. Oncol Rep 14: 73-79, 2005.
15. Yoshimura R, Inoue K, Kawahito Y, et al: Expression of 12-lipoxygenase in human renal cell carcinoma and growth prevention by its inhibitor. Int J Mol Med 13: 41-46, 2004.
16. Philips BJ, Dhir R, Hutzley J, Sen M and Kelavkar UP: Polyunsaturated fatty acid metabolizing 15-Lipoxygenase-1 (15-LO-1) expression in normal and tumorigenic human bladder tissues. Appl Immunohistochem Mol Morphol 16: 159-164, 2008.
17. Jack GS, Brash AR, Olson SJ, et al: Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 31: 1146-1154, 2000.
18. Jiang WG, Douglas-Jones A and Mansel RE: Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids 69: 275-281, 2003.
19. Yoshimura R, Matsuyama M, Tsuchida K, Kawahito Y, Sano H and Nakatani T: Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. J Urol 170: 1994-1999, 2003.
20. Brown HA and Marnett LJ: Introduction to lipid biochemistry, metabolism, and signaling. Chem Rev 111: 5817-6512, 2011.
21. Rini BI, Cohen DP, Lu DR, et al: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103: 763-773, 2011.
22. González-Núñez D, Claria J, Rivera F and Poch E: Increased levels of 12(S)-HETE in patients with essential hypertension. Hypertension 37: 334-338, 2001.